Protagonist Therapeutics, Inc.
PTGX
Rangering i aksjer
#2242
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aksjekurs
$138.22
Markedsverdi
$8.94B
Endring (1 dag)
0.16%
Endring (1 år)
84.29%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
Inntekter for Protagonist Therapeutics, Inc. (PTGX)
Inntekter i Jun 2026 TTM: $281.99M
Ifølge de nyeste økonomiske rapportene til Protagonist Therapeutics, Inc. er selskapets nåværende inntekter (TTM) $281.99M. I 2023 hadde selskapet inntekter på $60.00M en økning sammenlignet med inntektene i 2022, som var $26.58M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Protagonist Therapeutics, Inc. fra 2014 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $281.99M | -35.09% |
| 2024 | $434.43M | 624.06% |
| 2023 | $60.00M | 125.73% |
| 2022 | $26.58M | -2.84% |
| 2021 | $27.36M | -4.44% |
| 2020 | $28.63M | 12,293.07% |
| 2019 | $231.00K | -99.25% |
| 2018 | $30.93M | 54.14% |
| 2017 | $20.06M | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 4,376.83% |
US
|
|
| $2.23B | 690.09% |
US
|
|
| $15.74B | 5,483.25% |
AU
|
|
| $6.02B | 2,035.27% |
NL
|
|
| - | - |
CH
|
